Back to Awarded Treatment Trials
Awarded Trial: 02-STN-005
Grant ID
02-STN-005
Illness
Schizophrenia
Primary Drug/Intervention
Valcyclovir
Primary Dosage
1 gram twice daily
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Dickerson
Sample Size
65
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
PANSS, RBANS, WRAT III, MCAS
Results
Valcyvlovir 1 gram twice daily was administered to 65 outpatients with schizophrenia for 16 weeks in an open-label, adjunctive trial. In patients that were seropositive for cytomegalovirus (N=21), but not other herpesviruses, there was a significant improvement in the sum of PANSS positvie and negative symptom scores (Effect size =0.85).
Publication
Dickerson FB, Boronow JJ, Stallings CR, Origoni AE, Yolken RH. Reduction of symptoms by valcyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry. 2003 Dec;160(12):2234-6.
Link
http://www.ncbi.nlm.nih.gov/pubmed/14638597
PI Name
Faith Dickerson
Degree
MD
Center
N/A
Institution
Sheppard Pratt Health System Inc.
Address
6501 N. Charles Street, P.O. Box 6815
City or Town
Baltimore
State or Province
MD
Zip or Postal Code
21285
Country
USA
Email Address
fdickerson@sheppardpratt.org